IBDs are thought to involve uncontrolled innate and adaptive immunity against intestinal
self-antigens and
bacterial antigens. Mouse CA I is a major cecal
bacterial antigen in fecal extracts and is implicated in the pathogenesis of IBD. We show here that oral tolerization to CA I induced
antigen-specific protection from intestinal
inflammation in a murine model.
Oral administration of CA I but not irrelevant
antigen (KLH) ameliorated CD4(+)CD25(-) T cell transfer murine
colitis and DSS-induced murine
colitis. Next, we investigated the mechanisms involved in the
therapeutic effects of
oral administration, such as induction of ALDH1a2,
transcription factors,
cytokines, CD103(+)CD11c(+) DCs, and generation of Tregs.
Oral administration of CA I induced ALDH1a2
mRNA expression in the MLN and colon. When compared with PBS-treated mice, CA I-treated mice had higher Foxp3(+)CD4(+)CD25(+) Treg and CD103(+)CD11c(+) DC numbers in the MLN and colon; had higher TGF-β production in the MLN and colon; had lower RORγt
mRNA expression in the MLN and colon; and had lower
IL-17 mRNA expression and production in the MLN. These results demonstrate that
oral administration of CA I induced
antigen-specific immune tolerance by generating Foxp3(+)CD4(+)CD25(+) Tregs and inhibiting Th17 cells in a murine
colitis model, thus suggesting that oral tolerization with CA I is an effective therapeutic strategy for IBD regulation.